Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 in Major Depressive Disorder
NEW YORK, May 1, 2024. Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for central nervous system disorders, today announced the initiation of patient dosing with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 2, 2024 Category: Pharmaceuticals Source Type: clinical trials

Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
Conditions: Bladder Cancer Interventions: Drug: Enfortumab vedotin Sponsors: University of Texas Southwestern Medical Center; Astellas Pharma Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2024 Category: Research Source Type: clinical trials

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
Conditions: Interstitial Cystitis; Bladder Pain Syndrome Interventions: Drug: VNX001 Sponsors: Vaneltix Pharma, Inc.; Prevail Infoworks, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2024 Category: Research Source Type: clinical trials

Scientists Discover How an Essential Nutrient Enters the Brain
May 1, 2024 -- Researchers have discovered that choline, an essential nutrient vital for brain health, is actively transported from the bloodstream into the brain by a protein. The findings may inform the development of new drugs that take advantage... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 1, 2024 Category: Pharmaceuticals Source Type: clinical trials

NRx Pharmaceuticals Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
RADNOR, Pa., April 30, 2024, NRx Pharmaceuticals, Inc. ( " NRx Pharmaceuticals " , the " Company " ), a clinical stage pharmaceutical company today that its Breakthrough Therapy designated investigational drug NRX-101 vs lurasidone demonstrated a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 1, 2024 Category: Pharmaceuticals Source Type: clinical trials

Ingenium Therapeutics Novel NK Cell Therapy IGNK001 Receives Orphan Drug Designation From FDA
DAEJEON, Korea, April 30, 2024 /PRNewswire/ -- Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, announced today that its investigational therapy IGNK001 (Gengluecel) has been granted Orphan Drug Designation by the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 30, 2024 Category: Pharmaceuticals Source Type: clinical trials

A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
Conditions: Hallucinations and Delusions Associated With Alzheimer ' s Disease Psychosis; Hallucinations and Delusions Associated With Parkinson Disease Psychosis; Negative Symptoms of Schizophrenia Interventions: Drug: LY03017; Drug: LY03017-Placebo Sponsors: Luye Pharma Group Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials

Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654
Conditions: Effect of Drug Interventions: Drug: TP 3654 Sponsors: Sumitomo Pharma America, Inc. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials

A Pivotal Phase 3 Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia Interventions: Drug: Lisaftoclax (APG-2575); Other: Placebo; Drug: Azacitidine Injection Sponsors: Ascentage Pharma Group Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials

Study to Assess PK, Safety and Tolerability Early in Healthy Subjects
Conditions: Acute Ischemic Stroke Interventions: Drug: QHRD106 Injection; Drug: placebo Sponsors: Changzhou Qianhong Bio-pharma Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J.--(BUSINESS WIRE) April 29, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-10, a Phase 3 trial evaluating V116, the company’s investigational, adult-specific... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 29, 2024 Category: Pharmaceuticals Source Type: clinical trials

Lower Dose of Mpox Vaccine is Safe and Generates Six-Week Antibody Response Equivalent to Standard Regimen
April 27, 2024 -- A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to findings presented... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 27, 2024 Category: Pharmaceuticals Source Type: clinical trials

Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
Conditions: Cancer; Pulmonary Embolism; Thrombosis Interventions: Biological: Thrombin Generation Assay (TGA) Sponsors: Centre Hospitalier Universitaire de Saint Etienne; Diagnostica Stago; LEO Pharma; Ligue contre le cancer, France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2024 Category: Research Source Type: clinical trials

A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause
Conditions: Menopause Syndrome; Menopause; Hot Flashes Interventions: Drug: NOE-115 Sponsors: Noema Pharma AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2024 Category: Research Source Type: clinical trials

Analysis Identifies 50 New Genomic Regions Associated with Kidney Cancer Risk
April 26, 2024 -- In a new analysis of genetic susceptibility to kidney cancer, an international team of researchers has identified 50 new areas across the genome that are associated with the risk of developing kidney cancer. These insights could... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 26, 2024 Category: Pharmaceuticals Source Type: clinical trials